| Added by | pmartino |
|---|---|
| Group name | EquipePM |
| Item Type | Journal Article |
| Title | Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups |
| Creator | Amblard et al. |
| Author | I. Amblard |
| Author | F. Mercier |
| Author | D. L. Bartlett |
| Author | S. A. Ahrendt |
| Author | K. W. Lee |
| Author | H. J. Zeh |
| Author | E. A. Levine |
| Author | D. Baratti |
| Author | M. Deraco |
| Author | P. Piso |
| Author | D. L. Morris |
| Author | B. Rau |
| Author | A. a. K. Tentes |
| Author | J.-J. Tuech |
| Author | F. Quenet |
| Author | E. Akaishi |
| Author | M. Pocard |
| Author | Y. Yonemura |
| Author | G. Lorimier |
| Author | D. Delroeux |
| Author | L. Villeneuve |
| Author | O. Glehen |
| Author | G. Passot |
| Abstract | BACKGROUND: Peritoneal metastasis from biliary carcinoma (PMC) is associated with poor prognosis when treated with chemotherapy. OBJECTIVE: To evaluate the impact on survival of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and compare with conventional palliative chemotherapy for patients with PMC. MATERIAL AND METHODS: A prospective multicenter international database was retrospectively searched to identify all patients with PMC treated with a potentially curative CRS/HIPEC (CRS/HIPEC group). The overall survival (OS) was compared to patients with PMC treated with palliative chemotherapy (systemic chemotherapy group). Survival was analyzed using Kaplan-Meier method and compared with Log-Rank test. RESULTS: Between 1995 and 2015, 34 patients were included in the surgical group, and compared to 21 in the systemic chemotherapy group. In the surgical group, median peritoneal cancer index was 9 (range 3-26), macroscopically complete resection was obtained for 25 patients (73%). There was more gallbladder localization in the surgical group compared to the chemotherapy group (35% vs. 18%, p = 0.001). Median OS was 21.4 and 9.3 months for surgical and chemotherapy group, respectively (p=0.007). Three-year overall survival was 30% and 10% for surgical and chemotherapy group, respectively. CONCLUSION: Treatment with CRS and HIPEC for biliary carcinoma with peritoneal metastasis is feasible and may provide survival benefit when compared to palliative chemotherapy. |
| Publication | European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology |
| Volume | 44 |
| Issue | 9 |
| Pages | 1378-1383 |
| Date | 09 2018 |
| Journal Abbr | Eur J Surg Oncol |
| Language | eng |
| DOI | 10.1016/j.ejso.2018.04.023 |
| ISSN | 1532-2157 |
| Short Title | Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis |
| Library Catalog | PubMed |
| Extra | IMPACT: 3.060 PMID: 30131104 |
| Tags | Adult, Aged, Aged, 80 and over, Bile Duct Neoplasms, clinic, Cytoreduction Surgical Procedures, Female, Follow-Up Studies, France, Gallbladder, Hilar cholangiocarcinoma, Humans, Hyperthermia, Induced, Intra-hepatic cholangiocarcinoma, Klatskin, Male, Middle Aged, Peritoneal Neoplasms, Prognosis, Prospective Studies, Registries, Survival Rate |
| Date Added | 2018/09/16 - 11:48:24 |
| Date Modified | 2021/03/05 - 10:44:24 |
Institut de Recherche en Cancérologie de
